Wall Street brokerages expect that Amneal Pharmaceuticals Inc (NYSE:AMRX) will post $465.95 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Amneal Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $441.20 million and the highest estimate coming in at $474.50 million. Amneal Pharmaceuticals posted sales of $462.33 million in the same quarter last year, which would indicate a positive year over year growth rate of 0.8%. The business is scheduled to report its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.91 billion for the current year, with estimates ranging from $1.82 billion to $1.96 billion. For the next year, analysts expect that the firm will post sales of $1.97 billion, with estimates ranging from $1.86 billion to $2.04 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Amneal Pharmaceuticals.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its earnings results on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The company had revenue of $446.00 million for the quarter, compared to analyst estimates of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The business’s quarterly revenue was up 4.9% on a year-over-year basis.

Several research firms have recently commented on AMRX. Cantor Fitzgerald reduced their price target on shares of Amneal Pharmaceuticals from $35.00 to $14.00 and set an “overweight” rating on the stock in a research report on Wednesday. Raymond James upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to a “strong-buy” rating and set a $13.00 price target on the stock in a research report on Tuesday, May 21st. They noted that the move was a valuation call. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 7th. BMO Capital Markets lowered their price target on shares of Amneal Pharmaceuticals from $14.00 to $13.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Finally, Zacks Investment Research upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, seven have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $16.73.

Shares of Amneal Pharmaceuticals stock traded down $0.14 on Tuesday, hitting $7.20. 6,196 shares of the company were exchanged, compared to its average volume of 1,063,951. The stock has a market cap of $2.19 billion, a P/E ratio of 7.51, a P/E/G ratio of 0.45 and a beta of 1.63. Amneal Pharmaceuticals has a 1-year low of $7.15 and a 1-year high of $24.48. The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37.

In related news, SVP Joseph Todisco purchased 15,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were bought at an average price of $9.88 per share, for a total transaction of $148,200.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Pradeep Bhadauria purchased 7,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was bought at an average price of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 41,000 shares of company stock worth $387,300. 26.34% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Cresset Asset Management LLC acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at $29,000. Bessemer Group Inc. acquired a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $34,000. NumerixS Investment Technologies Inc boosted its stake in Amneal Pharmaceuticals by 52.1% during the 1st quarter. NumerixS Investment Technologies Inc now owns 3,052 shares of the company’s stock valued at $42,000 after purchasing an additional 1,045 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Amneal Pharmaceuticals by 28.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after purchasing an additional 1,477 shares during the period. Finally, Quantamental Technologies LLC boosted its stake in Amneal Pharmaceuticals by 34.0% during the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after purchasing an additional 1,700 shares during the period. Institutional investors own 36.05% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Read More: Call Option

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.